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Abstract
Background: Orally administered fluralaner effectively controls fleas and ticks on dogs for 12 weeks. This study
evaluates the flea control efficacy achieved with topically applied fluralaner in dogs.
Methods: This investigator-blinded, multi-center randomized, positive controlled study evaluated flea control
efficacy in dogs following a single owner-applied treatment of topical fluralaner. A positive control group received
three treatments, at 4-week intervals, of a commercial formulation of fipronil/(S)-methoprene. All dogs in
households randomized to the fluralaner group were dispensed an initial treatment at enrollment and a second
treatment at week 12 for an additional 3-week observation of treatment safety. Households with up to five healthy
dogs, all at least 12 weeks of age and weighing at least 2 kg (4.4 lb), were randomized in a ratio of 3:1 of fluralaner
to positive control. Within households, one primary dog with at least 10 live fleas at enrollment was randomly
selected. Flea counts were performed on all primary dogs every 4 weeks through week 12. Efficacy measurement
was based on reduction from baseline flea counts. Treatment was considered effective if geometric mean live flea
count reductions at weeks 4, 8, and 12 were 90% or greater and significantly different from counts at enrollment. In
addition, for each time point the arithmetic mean live flea counts, the efficacy based on arithmetic means, the
number and percentage of dogs with at least a 90% reduction in flea count, and the number and percentage of
flea free dogs were calculated. Statistical comparisons were also made between treatment groups.
Results: At 12 sites, across 10 states, 121 households (221 dogs) were randomized to receive fluralaner and 44
households (100 dogs) were randomized to receive the positive control. Fluralaner was demonstrated to be
significantly effective (all P ≤ 0.0001) at 4 weeks (99.8% reduction), 8 weeks (99.9%), and 12 weeks (99.9%). The
positive control was significantly different from baseline (all P≤ 0.0001) and showed a reduction of 81.2% at
4 weeks and was effective at 8 weeks (90.3%) and 12 weeks (93.0%). Arithmetic mean flea count reductions for the
fluralaner group at 4, 8, and 12 weeks were 99.8, 99.9, and 99.9%, respectively. For the positive control, arithmetic
mean flea count reductions were 58.8, 75.3, and 80.8% at 4, 8, and 12 weeks, respectively. No treatment-related
serious adverse events were reported in either group.
Conclusions: Owner-applied topical fluralaner treatment was safe in dogs and provided ≥ 99.8% flea control
efficacy for 12 weeks.
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Background
The fluralaner chewable tablet (Bravecto® chewable tab-
let, Merck Animal Health, Madison, NJ) sets a high bar
for flea efficacy for a topical follow-on product. In dogs
experimentally infested with fleas, the fluralaner chew-
able tablet showed early onset of flea killing at 2 h and
100% flea killing at 12 h post-administration [1]. This
high level of efficacy was sustained for 12 weeks, with
98.0% to 100% reductions in mean live flea counts at 8,
12, and 24 h after experimental reinfestations. A separ-
ate laboratory study found that 100% efficacy against
fleas was maintained for 122 days post-treatment, with a
corresponding elimination of flea egg laying [2]. The
prolonged efficacy of oral fluralaner treatment demon-
strated in laboratory studies translated into similar bene-
fits under field conditions: a single oral fluralaner
treatment of naturally infested dogs provided a signifi-
cant increase in the percentage of flea-free client-owned
dogs compared with three treatments at 28 day intervals
with orally administered spinosad [3]. In another study,
a single fluralaner treatment resolved flea allergy derma-
titis (FAD) signs and reduced owner-assessed scores of
their dogs’ pruritus [4]. Fluralaner acaricidal activity was
shown in laboratory studies where a single oral adminis-
tration produced 97.9% efficacy against Ixodes ricinus
within 8 h of treatment, and 100% at 12 h [5]. Fluralaner
is approved in many countries, including the United
States and throughout Europe, to provide 12 weeks ac-
tivity against several tick genera. The rapid onset of flur-
alaner acaricidal activity was shown to prevent the risk
of Dermacentor reticulatus transmission of Babesia canis
in a laboratory study [6]. Pharmacokinetic studies have
shown that topically administered fluralaner is distrib-
uted systemically and fleas are exposed at the time of
feeding [7].
This field study assessed the efficacy of owner-
administered topically applied fluralaner at home for flea
control compared with dogs in a positive control group
that received three treatments with fipronil/(S)-metho-
prene (Frontline® Plus for Dogs, Merial Limited, Duluth,
Georgia).
Methods
The study protocol, finalized in early 2013, used then-
current guidelines for evaluating flea and tick parasiticides
[8]. It also complied with Good Clinical Practice (VICH
GL9) and the International Guiding Principles for Bio-
medical Research Involving Animals. Written informed
consent was obtained from each owner for all household
dogs prior to any screening activities. Enrollment eligibil-
ity included households that had no more than five dogs,
all of which were at least 12 weeks of age, weighed at least
2 kg, and were in generally good health; and that at least
one dog in the household had a minimum of 10 live fleas
counted prior to enrollment. There were no breed or gen-
der restrictions, but households with pregnant or lactating
dogs were not eligible for enrollment. Households in
which dogs had exposure to non-confined pets, other than
dogs, that could harbor fleas (e.g. cats) were not eligible.
There were also restrictions on the pre-enrollment/histor-
ical use of any approved (in the USA, as this was a USA
study) flea control medications or products, based on the
approved label duration. Products labeled for 12-week use
had a minimum 84-day washout, products labeled for
monthly use had a minimum 30-day washout, products la-
beled for used every 2 weeks had a minimum 14-day
washout, and products labeled for weekly use had a 7-day
washout.
Within each of the 12 participating clinics, enrolled
households were randomly assigned between two treat-
ment groups. No single clinic was permitted to contrib-
ute more than 40% of the households assigned to either
group. The groups were:
1. Fluralaner (28% w/v) topical solution for dogs,
dispensed for owner administration on Day 0. The
efficacy evaluation phase of the study lasted for
12 weeks. A second dose was dispensed after the
12-week efficacy evaluation and dogs were followed
for an additional 3 weeks (21 days, until Day 105,
Week 15) for additional safety assessment. At least
100 households were targeted for assignment to the
fluralaner group. The product was provided to
clinics as single-dose applicators in five sizes,
containing 112.5 mg, 250 mg, 500 mg, 1,000 mg or
1,400 mg, in volumes of 0.4, 0.89, 1.79, 3.57 and
5 ml, respectively. The targeted dose range for each
dog was 25–56 mg/kg.
2. Fipronil/(S)-methoprene spot-on solution was
dispensed for application once every 28 days for
three doses. A minimum of 33 households were
targeted for enrollment into this group. This product
remained in its commercial packaging containing
volumes of 0.67, 1.34, 2.68 or 4.02 ml.
At each site, households were assigned to treatment
according to a randomized complete block design, with
order of entry into the study as the blocking factor and
assignment of dogs to treatment within blocks in a ratio
of 3:1 of fluralaner to positive control households. A pri-
mary dog from each household was randomly selected
from dogs with at least 10 live fleas on initial examin-
ation. Separate randomization tables were provided to
each site for assignment of households to treatment
group and selection of the primary dog. All dogs in a
household were assigned to the same treatment group.
Each clinic had at least one dispensing administrator
who was responsible for randomization and dispensing
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all treatments to owners, and ensured that blinded
personnel remained blinded by dispensing study prod-
ucts in paper bags. Administrators did not participate in
the collection or recording of flea count data or the as-
sessment of FAD. Study personnel who participated in
the collection or recording of flea count data or the as-
sessment of FAD through the final visit were masked to
treatment assignment.
All treatments were administered at home by dog
owners, who were not blinded. For households random-
ized to the fluralaner group, owners were provided in-
structions on application using the tube, including
parting the hair, placing the tip on the skin and squeez-
ing out the contents onto one or more spots in amounts
that would limit risk of topical dispersion from any
treatment location. Owners of dogs randomized to the
fipronil-methoprene group were instructed to dose ac-
cording to label directions.
Enrollments were completed during the first clinic visit,
during which treatments were dispensed and blood and
urine samples collected for baseline clinical pathology
data. Owners were required to bring their dogs into the
clinic for re-examination visits approximately 4, 8, and
12 weeks after enrollment (on Days 28 [±2], 56 [±3] and
84 [±3]). For households randomized to fipronil-
methoprene treatment, study participation ended at
12 weeks. For households randomized to the fluralaner
group, dogs were retreated with topical fluralaner at
84 days and were required to return for examination at
Day 105 (±3), 3 weeks after the second treatment.
From enrollment until week 12 (Day 84), owners were
asked to avoid any premise treatments for environmental
flea control, either in their house or on their property.
No concomitant treatments for flea and/or tick infesta-
tions were permitted during the study period, and the
investigator or designee was asked to observe an ad-
equate washout period (consistent with any US-
approved labeling) for any such treatments received
prior to enrollment. Concomitant treatments for disor-
ders other than flea and tick infestations were permitted,
if they were not expected to interfere with assessments
of flea and tick infestations. For example, treatments di-
rected at the prevention and control of internal parasite
infestations (including heartworm and gastrointestinal
parasites) were permitted, if any product used was not
labeled for flea or tick control. Treatment that could
affect assessment of signs of FAD (for example, steroids,
antihistamines, creams, ointments, baths, etc.) was per-
missible. However, data from any such treated dog were
excluded from the summaries of signs of FAD after
treatment. Grooming, bathing, swimming, and other
water activities were permitted during the study, with
some exceptions. To avoid any effect on recovery of fleas
and ticks, grooming and bathing were not allowed
within 72 h before any scheduled re-examination
through 12 weeks (Day 84). In addition, bathing, swim-
ming, and other water activities were not allowed for
72 h after application of any study treatment.
Owners were instructed to observe their dogs for any
adverse events (AEs), and to document such observa-
tions and report them as soon as they occurred or at the
next scheduled visit. At each re-examination, primary
dogs received a flea count using a flea comb for at least
10 min. The flea count could stop when the counter was
confident that all fleas had been recovered.
Skin examinations at each visit included a veterinarian’s
assessment of the presence of six signs of FAD (erythema,
alopecia, papules, scales, crusts, and excoriations) together
with a severity (mild, moderate, severe) assessment.
The primary efficacy endpoint was the reduction in mean
flea counts, with household as the experimental unit. Each
household was represented by one primary dog.
Efficacy assessment
Arithmetic and geometric mean live flea counts were
calculated separately for each treatment group at each
assessment and the percentage reduction at each time






where D0 =mean live flea count at baseline of primary
dogs; and Dx =mean live flea count on Day x (x = 28
[4 weeks], 56 [8 weeks] or 84 [12 weeks]) of primary dogs.
Both geometric means and arithmetic means were com-
pared using the live flea counts and log-transformed live
flea counts (log [live flea count + 1]) for each household
(represented by one primary dog). A mixed linear model
with repeated measures was used for the analysis. The
model included treatment, visit and treatment*visit as
fixed effects, site as a random effect, and household as the
subject with repeated measures. A Kenward-Rogers ad-
justment was used to determine the denominator degrees
of freedom for hypothesis testing. Akaike’s Information
Criterion (AIC) was used as the criterion to select the co-
variance structure for repeated measures. Least squares
means were used for comparisons and for the log-
transformed data, the least squares means were back-
transformed to obtain the estimates of geometric mean
live flea counts. Within each treatment group, the live flea
counts at each post-treatment visit (Day 28, 56 and 84)
were compared with that at the baseline (Visit 1). At each
visit, live flea counts were compared between the two
treatment groups. Two-sided t-tests at a 5% level of sig-
nificance were used for all pairwise comparisons. SAS ver-
sion 9.3 was the primary software used for analysis.
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Treatment was considered effective at a given time point
if the mean (geometric or arithmetic) live flea count
reduction was 90% or greater and significantly different
(P ≤ 0.05) from baseline.
Numbers and percentages of primary dogs that
showed at least 90% reduction in flea burden, as well as
the numbers and percentages of primary dogs with zero
fleas counted in each treatment group at each visit were
calculated. A non-parametric asymptotic approach was
used to test the differences of the percentages between
treatment groups. The non-parametric analyses were
performed using StatXact version 9. The study was only
designed to perform statistical comparisons of the flea
counts. Signs of FAD and AEs were only examined de-
scriptively. Thus, no P-values were presented for these
outcomes.
Results
Between May and October 2013, 321 dogs from 165
households were enrolled at 12 sites across 10 states:
Alabama (one site), Florida (one), Illinois (one), Indiana
(one), Kansas (one), Louisiana (one), Maine (one), Penn-
sylvania (two), Tennessee (one), and Texas (two). There
were 121 households (i.e. 121 primary dogs) with a total
of 221 dogs randomized to the fluralaner group (51.2%
single-dog households), and 44 households with a total
of 100 dogs randomized to the fipronil-methoprene
group (36.4% single-dog households). Gender distribu-
tion, age ranges, and body weights were generally similar
between the groups (Table 1). The youngest dogs en-
rolled in the study were 13 weeks of age in the fluralaner
group and 14 weeks of age in the fipronil-methoprene
group; 4.5% of fluralaner dogs and 10.0% of fipronil-
methoprene dogs were less than 26 weeks. Mixed breeds
comprised 35.3 and 40.0% of fluralaner and fipronil-
methoprene dogs, respectively.
In both treatment groups, primary dogs occasionally
missed visits during this field study, and therefore did
not have flea count data generated. In the fluralaner
group, there were six dogs that missed at 4 weeks, 12
dogs that missed at 8 weeks, and 11 dogs that missed at
12 weeks. In the fipronil-methoprene group, there were
seven dogs that missed at 4 weeks, eight dogs that
missed at 8 weeks, and eight dogs that missed at
12 weeks. In addition, in both treatment groups there
were some primary dogs for which flea count data were
generated, but the results excluded from flea efficacy cal-
culations for reasons including bathing within 72 h prior
to a flea count or 72 h after administration of a treat-
ment, incorrect dosing, or insecticidal treatment of the
household. In the fluralaner group, data from one pri-
mary dog were excluded at the initial count, data from
five dogs were excluded at 4 weeks, data from four dogs
were excluded at 8 weeks, and data from six dogs were
excluded at 12 weeks. In the fipronil-methoprene group,
data from one primary dog were excluded at 4 weeks
and data from three dogs were excluded at 12 weeks.
In the fluralaner group, treatment was demonstrated
to be effective by geometric means (percent reduction ≥
90% vs baseline) at 4 weeks (99.8% reduction), 8 weeks
(99.9%) and 12 weeks (99.9%), and flea count reductions
were significantly different from baseline (all P < 0.0001)
(Table 2). Arithmetic mean efficacy of the fluralaner
group was 99.8%, 99.9% and 99.9% at weeks 4, 8, and 12,





Age (years) Mean (SD) 4.5 (3.41) 4.9 (3.70)
Range 0.3a−17.0 0.3b−16.3
Weight (lb) Mean (SD) 35.0 (25.84) 37.8 (29.08)
Range 4.4−112.0 4.4−136.0
Gender Female, Intact 41 (18.6%) 21 (21.0%)
Female, Spayed 70 (31.7%) 29 (29.0%)
Male, Intact 60 (27.1%) 25 (25.0%)
Male, Neutered 50 (22.6%) 25 (25.0%)
Distribution of household sizes (no. of dogs)
1 62 (51.2%) 16 (36.4%)
2 30 (24.8%) 14 (31.8%)
3 19 (15.7%) 5 (11.4%)
4 8 (6.6%) 4 (9.1%)
5 2 (1.7%) 5 (11.4%)
ain the fluralaner group, the youngest dogs enrolled were 13 weeks of age; 10 (10/221 = 4.5%) were less than 26 weeks of age
bin the fipronil group, the youngest dogs enrolled were 14 weeks of age; 10 (10/100 = 10.0%) were less than 26 weeks of age
Meadows et al. Parasites & Vectors  (2017) 10:36 Page 4 of 8
respectively (Table 2, Fig. 1, all P < 0.0001). The percent-
ages of individual fluralaner-treated primary dogs with
a ≥ 90% reduction in flea burden from baseline were
100% at 4 weeks, 100% at 8 weeks, and 98.1% at
12 weeks. The percentages of individual fluralaner-
treated primary dogs with 0 fleas detected (i.e. a 100%
reduction) were 84.5% at 4 weeks, 93.3% at 8 weeks, and
93.3% at 12 weeks (Table 2).
In the fipronil-methoprene group, treatment was dem-
onstrated effective based on geometric means at weeks 8
(90.3%) and 12 (93.0%) (Table 2), and were significantly
different from baseline (all P < 0.0001). At 4 weeks, the
reduction by geometric means was 81.2%, which was less
than 90% but was significantly different from baseline (P
< 0.0001). Arithmetic mean efficacy of the fipronil-
methoprene group was 58.8, 75.3 and 80.8% at weeks 4,
8 and 12, respectively (Table 2, Fig. 1, all P ≤ 0.0132).
The percentages of individual fipronil-methoprene-
treated primary dogs with a ≥ 90% reduction in flea bur-
den from baseline were 38.9% at 4 weeks, 55.6% at
8 weeks, and 54.5% at 12 weeks. The percentages of in-
dividual fipronil-methoprene-treated primary dogs with
0 fleas detected (i.e. a 100% reduction) were 13.9% at
4 weeks, 30.6% at 8 weeks, and 30.3% at 12 weeks.
In both groups, there was improvement of FAD signs
in both the fluralaner topical and positive control treated
Table 2 Flea counts for primary dogs enrolled in a field flea-efficacy evaluation of fluralaner topical solution and fipronil/(S)-




(Week 4, Day 28)
Visit 3
(Week 8, Day 56)
Visit 4
(Week 12, Day 84)
Number of primary dogs
Fluralaner topical solution 120 110 105 104
Fipronil/(S)-methoprene spot-on solution 44 36 36 33
Arithmetic mean flea count (95% CI)
Fluralaner topical solution 149.0 (109.9–188.2) 0.2 (0.1–0.4) 0.2 (0.0–0.3) 0.1 (0.0–0.2)
Fipronil/(S)-methoprene spot-on solution 124.7 (78.1–171.3) 51.4 (16.9–86.0) 30.8 (10.8–50.9) 24.0 (3.6–44.4)
P-value for comparisona t(161.8) = 0.67, P = 0.5011 t(152.3) = -4.96, P < 0.0001 t(150.3) = –5.35, P < 0.0001 t(106.9) = -4.22, P < 0.0001
% efficacy (reduction from baseline) based on arithmetic means
Fluralaner topical solution na 99.8 99.9 99.9
P-value for comparison to baselinea na t(162.9) = 8.04, P < 0.0001 t(162.0) = 8.05, P < 0.0001 t(161.5) = 7.95, P < 0.0001
Fipronil/(S)-methoprene spot-on solution na 58.8 75.3 80.8
P-value for comparison to baselinea na t(164.4) = 2.51, P = 0.0132 t(162.4) = 3.10, P = 0.0023 t(162.6) = 2.93, P = 0.0039
Geometric mean flea count (95% CI)
Fluralaner topical solution 68.9 (55.2–85.9) 0.1 (0.1–0.2) 0.1 (0.0–0.1) 0.1 (0.0–0.1)
Fipronil/(S)–methoprene spot-on solution 66.6 (47.6–93.1) 12.5 (6.7–22.8) 6.4 (3.1–12.4) 4.7 (2.2–9.0)
P-value for comparisona t(158.2) = 0.154, P = 0.8782 t(145.6) = -14.13, P < 0.0001 t(145.9) = -10.77, P < 0.0001 t(134.4) = -10.17, P < 0.0001
% efficacy (reduction from baseline) based on geometric means
Fluralaner topical solution na 99.8 99.9 99.9
P-value for comparison to baselinea na t(158.1) = 34.41, P < 0.0001 t(156.3) = 32.47, P < 0.0001 t(155.7) = 31.83, P < 0.0001
Fipronil/(S)-methoprene spot-on solution na 81.2 90.3 93.0
P-value for comparison to baselinea na t(165.5) = 8.32, P < 0.0001 t(161.1) = 10.40, P < 0.0001 t(165.5) = 10.95, P < 0.0001
% of primary dogs with at least 90% reduction from baseline flea count
Fluralaner topical solution na 100.0 100.0 98.1
Fipronil/(S)-methoprene spot-on solution na 38.9 55.6 54.5
P-value for comparisonb na Z = -9.11, P < 0.0001 Z = -7.26, P < 0.0001 Z = -6.61, P < 0.0001
% of flea-free primary dogs
Fluralaner topical solution na 84.5 93.3 93.3
Fipronil/(S)-methoprene spot-on solution na 13.9 30.6 30.3
P-value for comparisona na Z = -7.83, P < 0.0001 Z = -7.76, P < 0.0001 Z = -7.62, P < 0.0001
aP-value for comparison of model least squares means parameter estimates
bP-value for comparison of percentages using non-parametric asymptotic approach and Standardized Statistic
Abbreviation: na value or calculation is not applicable
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groups (Table 3). The most common manifestation of
FAD observed in study dogs was erythema, which at en-
rollment was recorded for 83 of 221 (37.6%) dogs in the
fluralaner group and 36 of 100 (36.0%) dogs in the
fipronil-methoprene group. At 12 weeks, the percentage
of eligible dogs in which this sign was seen to have re-
solved was 91.4% in the fluralaner and 60.0% in the
fipronil-methoprene group.
No serious adverse events were reported in either study
group. All adverse events were unremarkable throughout
the study. A review of study records and owner diaries
showed that vomiting was the most frequent event in both
groups, affecting 6.3% of fluralaner treated dogs and 6.0%
of fipronil-methoprene treated dogs. Other adverse events
occurred at generally similar rates in both groups, al-




























































Fig. 1 Arithmetic mean flea counts and percent reduction from baseline to weeks 4, 8 and 12 for topical fluralaner or fipronil/(S)-methoprene
treated dogs (bars indicate arithmetic flea counts; lines indicate percentage reductions from baseline)
Table 3 Proportion of dogs showing Flea Allergy Dermatitis signs at the initial visit and 12 week recheck following treatment with





Erythema Number of dogs with sign at initial exam that were also eligible for
re-examination at 12 weeks
58 25
% of dogs with lesion resolved at 12-week re-examination 91.4 60.0
Alopecia Number of dogs with sign at initial exam that were also eligible for
re-examination at 12 weeks
43 19
% of dogs with lesion resolved at 12-week re-examination 86.0 78.9
Papules Number of dogs with sign at initial exam that were also eligible for
re–examination at 12 weeks
32 6
% of eligible dogs with lesion resolved at 12-week re-examination 96.9 100.0
Scales Number of dogs with sign at initial exam that were also eligible for
re-examination at 12 weeks
27 11
% of eligible dogs with lesion resolved at 12-week re-examination 92.6 72.7
Crusts Number of dogs with sign at initial exam that were also eligible for
re-examination at 12 weeks
28 10
% of eligible dogs with lesion resolved at 12-week re-examination 100.0 80.0
Excoriation Number of dogs with sign at initial exam that were also eligible for
re-examination at 12 weeks
25 6
% of eligible dogs with lesion resolved at 12-week re-examination 100.0 83.3
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methoprene treated dogs and 2.7% of fluralaner treated
dogs; alopecia (focal hair loss) and decreased appetite were
reported in more fluralaner treated dogs (4.1 and 2.0%, re-
spectively) than fipronil-methoprene treated dogs (1.4 and
0.0%, respectively) (Table 4).
Clinical pathology for both groups was unremarkable,
with no clinically relevant observations suggestive of
pathologic trends, and only occasional isolated depar-
tures from normal reference ranges in blood and urine
analyses. There were no clinically relevant clinical path-
ology differences between the fluralaner and fipronil-
methoprene groups.
Discussion
Treatment with topical fluralaner provided a high and
persistent level of flea control efficacy throughout the
12-week duration of efficacy evaluation. This efficacy
was greater than the flea control efficacy of the fipronil-
methoprene treatment at several time points. Results of
this field study seen with the topical fluralaner formula-
tion align with results of a study with a similar design
that assessed the chewable fluralaner formulation [3]. In
both studies, a single treatment/application resulted in
a > 99% reduction in live flea counts within 4 weeks, and
sustained flea count reductions of > 99% through
12 weeks; more than 80% of fluralaner-treated dogs were
free of fleas at 4 weeks, and more than 90% were free of
fleas at the 8- and 12-week assessments.
The overall flea control results for fluralaner compared
favorably with those of fipronil-methoprene. Furthermore,
the results observed are also consistent with findings in
other field studies. For instance, in the aforementioned
field trial with the oral fluralaner formulation, the oral
fluralaner group had > 90% of dogs flea-free after a single
treatment [3]. In an earlier spinosad study in which
fipronil-methoprene was a comparator product, only 38%
of dogs in the fipronil-methoprene group were free of fleas
after three consecutive monthly treatments [9], aligning
with our results of 30% of flea-free dogs receiving three
owner-applied fipronil-methoprene treatments at 4 week
intervals. Another 2013 study comparing indoxacarb to
fipronil-methoprene for flea control in dogs and cats in
private homes showed that 16% of fipronil-methoprene-
treated pets were flea free after two owner-applied
monthly treatments [10].
There were households in this study that failed to
achieve adequate flea control in fipronil-methoprene
treated dogs. Previous reports [9, 10] suggested that treat-
ment failures with fipronil /(S)-methoprene may have
been caused by: inherent variability of topical administra-
tion linked to incomplete owner compliance with dosing
directions; to effects of bathing; to climatic conditions; or
to other unknown factors. In this current study, the fact
that topically-applied fluralaner was highly effective sug-
gest that owners in the study understood topical applica-
tion and reduce the likelihood that owner misapplication
explains the results observed in the fipronil-methoprene
dogs. Also, bathing or exposure to water within specified
time periods relative to dosing was documented in this
study, and data points affected by these events were ap-
propriately excluded. Furthermore, household flea control
failures for fipronil-methoprene dogs occurred in both
southern enrolling clinics (in a warmer climate that would
be expected to have substantial flea burdens), and in
northern clinics, where generally lighter flea burdens
might be expected.
As would be expected from the use of highly effective
flea control measures, and matching findings in earlier field
studies, treatment with topical fluralaner was followed by
resolution of FAD signs in treated dogs [3, 4, 11].
Both the topical fluralaner and topical fipronil-
methoprene products were well tolerated in this study.
There were no detectable effects of either product on
clinical pathology tests (baseline and week 12 for
fipronil-methoprene dogs; baseline, week 12, and week
15 for fluralaner dogs).
Conclusions
In conclusion, the fluralaner topical solution was well
tolerated in this study and was highly effective in remov-
ing flea infestations present at the time of initial treat-
ment, and in preventing reinfestation. The results show
that owner applied fluralaner topical solution can pro-
vide convenient and reliable flea control for veterinar-
ians and dog owners who prefer the topical route.
Abbreviation
FAD: Flea allergy dermatitis
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